[go: up one dir, main page]

DE60233061D1 - Alphavirus replikon-vektorsysteme - Google Patents

Alphavirus replikon-vektorsysteme

Info

Publication number
DE60233061D1
DE60233061D1 DE60233061T DE60233061T DE60233061D1 DE 60233061 D1 DE60233061 D1 DE 60233061D1 DE 60233061 T DE60233061 T DE 60233061T DE 60233061 T DE60233061 T DE 60233061T DE 60233061 D1 DE60233061 D1 DE 60233061D1
Authority
DE
Germany
Prior art keywords
replication
alphavirus replicon
vector systems
replicon vector
alphavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60233061T
Other languages
English (en)
Inventor
Jonathan F Smith
Kurt I Kamrud
Jonathan O Rayner
Sergey A Dryga
Ian J Caley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alphavax Inc
Original Assignee
Alphavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23234980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60233061(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alphavax Inc filed Critical Alphavax Inc
Application granted granted Critical
Publication of DE60233061D1 publication Critical patent/DE60233061D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Memory System Of A Hierarchy Structure (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60233061T 2001-09-06 2002-09-06 Alphavirus replikon-vektorsysteme Expired - Lifetime DE60233061D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31772201P 2001-09-06 2001-09-06
PCT/US2002/028610 WO2003023026A1 (en) 2001-09-06 2002-09-06 Alphavirus replicon vector systems

Publications (1)

Publication Number Publication Date
DE60233061D1 true DE60233061D1 (de) 2009-09-03

Family

ID=23234980

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60233061T Expired - Lifetime DE60233061D1 (de) 2001-09-06 2002-09-06 Alphavirus replikon-vektorsysteme

Country Status (9)

Country Link
US (2) US7045335B2 (de)
EP (1) EP1432791B2 (de)
JP (1) JP4790984B2 (de)
AT (1) ATE437222T1 (de)
AU (1) AU2002327614B2 (de)
CA (1) CA2460269C (de)
DE (1) DE60233061D1 (de)
ES (1) ES2330202T5 (de)
WO (1) WO2003023026A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
GB0019745D0 (en) * 2000-08-10 2000-09-27 Univ Surrey Gene expression element
ATE437222T1 (de) 2001-09-06 2009-08-15 Alphavax Inc Alphavirus replikon-vektorsysteme
ES2559002T3 (es) 2001-10-23 2016-02-10 Psma Development Company, L.L.C. Anticuerpos contra PSMA
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
BR122019005271B1 (pt) * 2002-12-13 2020-10-13 Alphavax, Inc. método para a preparação de partículas de replicon de alfavírus (arps)
JP4991108B2 (ja) 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
DK1608762T3 (da) * 2003-03-20 2014-04-07 Alphavax Inc Forbedrede alphavirusreplikoner og hjælperkonstrukter
EP1651666B1 (de) 2003-07-11 2009-05-27 Alphavax, Inc. Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
US20050257277A1 (en) * 2004-05-17 2005-11-17 Xiaobin Lu Regulation of transcription with a cis-acting ribozyme
ATE420965T1 (de) 2004-05-18 2009-01-15 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
CA2567047C (en) 2004-05-25 2015-06-30 Zequn Tang Alphavirus replicon packaging constructs
CA2572921C (en) * 2004-07-09 2017-01-03 The University Of North Carolina At Chapel Hill Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants
US7332322B2 (en) * 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
US7998733B2 (en) * 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
AU2006302794B2 (en) * 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
US20100247565A1 (en) * 2005-06-29 2010-09-30 Ilya Frolov Chimeric sindbis-eastern equine encephalitis virus and uses thereof
WO2008033966A2 (en) * 2006-09-12 2008-03-20 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
WO2008085557A2 (en) 2006-09-12 2008-07-17 Alphavax, Inc. Alphavirus replicon particles encoding il- 12 as immunological adjuvants
NZ576563A (en) * 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
WO2008127307A2 (en) * 2006-11-09 2008-10-23 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using prime-boost approach
US8748591B2 (en) * 2007-04-17 2014-06-10 The Board Of Regents Of The University Of Texas System Chimeric sindbis-western equine encephalitis virus and uses thereof
CA2689588C (en) * 2007-06-21 2016-08-23 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
US20090162395A1 (en) * 2007-09-26 2009-06-25 Crowe Jr James E Vaccine for rsv and mpv
US20100040650A1 (en) * 2008-05-30 2010-02-18 Crowe Jr James E Virus-Like paramyxovirus particles and vaccines
WO2009156155A1 (en) * 2008-06-25 2009-12-30 Probiogen Ag Cell line for propagation of highly attenuated alphaviruses
WO2010040023A2 (en) 2008-10-03 2010-04-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for protein delivery
EP2370584B1 (de) 2008-12-01 2014-11-05 Alphavax, Inc. Verwendung von mikro-RNS zur Kontrolle von Virus Helfernukleinsäuren
EP2416662B1 (de) 2009-04-08 2015-03-25 Alphavax, Inc. Trp2 exprimierende alphavirus-replikon-partikel
US20130195914A1 (en) * 2010-04-12 2013-08-01 Viracine Therapeutics Corporation Expression Of Positive Sense Single Stranded RNA Virus And Uses Thereof
CN106421773A (zh) * 2010-07-06 2017-02-22 诺华股份有限公司 自我复制rna分子的病毒样递送颗粒
DK2590626T3 (en) 2010-07-06 2016-01-25 Glaxosmithkline Biolog Sa Liposomes with lipids having a favorable pKa of RNA for bringing
SI2591114T1 (sl) 2010-07-06 2016-10-28 Glaxosmithkline Biologicals S.A. Imunizacija velikih sesalcev z majhnimi odmerki RNA
US9801897B2 (en) 2010-07-06 2017-10-31 Glaxosmithkline Biologicals Sa Delivery of RNA to trigger multiple immune pathways
FI4043040T3 (fi) * 2010-08-31 2023-04-04 Glaxosmithkline Biologicals Sa Pieniä liposomeja immunogeeniä koodaavan rna:n toimittamiseksi
DK4066856T3 (da) 2010-08-31 2022-12-19 Glaxosmithkline Biologicals Sa Pegylerede liposomer til afgivelse af immunogen-kodende RNA
US20140030292A1 (en) 2010-10-11 2014-01-30 Novartis Ag Antigen delivery platforms
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
US20120107355A1 (en) 2010-10-27 2012-05-03 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
JP2014520806A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー Ｒｎａ分子の送達のための有用なｎ：ｐ比を有するリポソーム
WO2013066665A1 (en) 2011-10-19 2013-05-10 Harrisvaccines, Inc Method of rapidly producing improved vaccines for animals
BR112014012162B1 (pt) 2011-12-21 2021-09-08 Apse, Llc Processo para purificar quantidade de partículas semelhantes a vírus (vlps)
EP2831225A1 (de) 2012-03-26 2015-02-04 The United States of America, As Represented by the Secretary, Dept. of Health & Human Services Office of Technology Transfer Verabreichung von verkapselter rna an säugerzellen
PL2852671T3 (pl) 2012-05-21 2019-06-28 The Regents Of The University Of California Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna
AU2014281061B2 (en) 2013-06-19 2019-07-18 Rnaissance Ag Llc Compositions and methods using capsids resistant to hydrolases
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
CN106232807A (zh) 2013-12-16 2016-12-14 美利坚合众国, 由健康及人类服务部部长代表 通过使用vlp复制子投递ii类mhc抗原的癌症免疫疗法
AU2015311706A1 (en) 2014-09-07 2017-02-02 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
KR20240015743A (ko) 2017-01-07 2024-02-05 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
CA3057171A1 (en) 2017-03-30 2018-10-04 The University Of Queensland Chimeric polypeptides containing virus fusion ectodomain and complementary heptad repeats and uses thereof
EP3687561A4 (de) 2017-09-01 2021-06-09 The Australian National University Immunregulatorische moleküle und deren verwendung
US20190142974A1 (en) 2017-10-13 2019-05-16 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
KR20200090927A (ko) 2017-12-19 2020-07-29 아카우오스, 인크. 내이에 대한 치료적 항체의 aav-매개 전달
BR112020012190A8 (pt) 2017-12-20 2023-04-11 Vlp Therapeutics Llc Partícula de replicon de alfavírus
EP3758682A4 (de) 2018-02-26 2021-12-15 Antolrx, Inc. Tolerogene liposome und verfahren zur verwendung davon
EP3830109A4 (de) * 2018-08-03 2022-05-18 Uab Research Foundation Verfahren und zusammensetzungen für eine alphavirus-impfung
CN114126666A (zh) 2019-04-28 2022-03-01 西莱克塔生物科技公司 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法
EP3976802A1 (de) 2019-05-28 2022-04-06 Selecta Biosciences, Inc. Verfahren und zusammensetzungen für abgeschwächte immunantwort auf antivirale transfervektoren
EP4007814A1 (de) 2019-07-26 2022-06-08 Akouos, Inc. Verfahren zur behandlung von hörverlust unter verwendung eines sekretierten zielproteins
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
US11730799B2 (en) * 2019-10-18 2023-08-22 University Of Iowa Research Foundation Cancer vaccines and methods of producing and using same
CA3162690A1 (en) 2019-12-31 2021-07-08 Minoru S. H. Ko Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
TW202200605A (zh) 2020-03-09 2022-01-01 美商亞克圖羅斯醫療公司 冠狀病毒疫苗組成物和方法
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
IL297564A (en) 2020-04-30 2022-12-01 Vlp Therapeutics Inc Cytokine immunotherapy
US20230212606A1 (en) 2020-05-13 2023-07-06 Akouos, Inc. Compositions and methods for treating kcnq4-associated hearing loss
EP4165195A2 (de) 2020-05-13 2023-04-19 Akouos, Inc. Zusammensetzungen und verfahren zur behandlung von slc26a4-assoziiertem hörverlust
WO2022036170A1 (en) 2020-08-14 2022-02-17 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
CR20230228A (es) 2020-12-01 2023-07-18 Akouos Inc Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
IL304006A (en) 2020-12-29 2023-08-01 Akouos Inc Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
WO2023048758A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Dried nanoparticle compositions
EP4405372A1 (de) 2021-09-22 2024-07-31 HDT Bio Corp. Sars-cov-2-rna-impfstoffzusammensetzungen und verfahren zur verwendung
EP4408872A1 (de) 2021-09-30 2024-08-07 Akouos, Inc. Zusammensetzungen und verfahren zur behandlung von kcnq4-assoziiertem gehörverlust
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
EP4473011A1 (de) 2022-02-02 2024-12-11 Akouos, Inc. Anti-vegf-antikörperkonstrukte und zugehörige verfahren zur behandlung von vestibulärem schwannoma-assoziierten symptomen
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
CN119563028A (zh) 2022-05-12 2025-03-04 尚威天成信使核糖核酸治疗公司 具有分泌抗原和免疫调节物的合成自扩增mRNA分子
WO2024009280A1 (en) 2022-07-08 2024-01-11 Baylor College Of Medicine Integrated stress response inhibitors and methods of using the same
WO2024126423A1 (en) 2022-12-12 2024-06-20 Precision NanoSystems ULC Lipid nanoparticles lyophilization methods and compositions
WO2024229309A2 (en) 2023-05-03 2024-11-07 Manifold Biotechnologies, Inc. Methodsand compositions for high-throughput protein delivery, screening, and detection
EP4474015A1 (de) 2023-06-05 2024-12-11 Veterna Srl Noda-ähnliche rna-impfstoffe, ihre herstellung und verwendung

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138854B1 (de) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigen aktive aminosäuresequenzen
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
NZ225583A (en) 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
US6770283B1 (en) 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US20020102273A1 (en) 1995-08-08 2002-08-01 Robert B. Grieve Use of alphavirus expression vectors to produce parasite anitgens
WO1994017813A1 (en) 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
RU2057377C1 (ru) 1993-08-23 1996-03-27 Уральский электрохимический комбинат Способ переработки оружейного высокообогащенного урана и его сплавов в топливный материал для атомных реакторов
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DK0814154T3 (da) 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
JPH11504802A (ja) * 1994-11-30 1999-05-11 カイロン コーポレイション 組換えアルファウイルスベクター
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5639650A (en) 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
AU2809897A (en) 1996-04-23 1997-11-12 Wistar Institute Of Anatomy And Biology, The Novel human cytomegalovirus dna constructs and uses therefor
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
AU3447097A (en) 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
JP2965908B2 (ja) 1996-07-05 1999-10-18 株式会社精工技研 調温液体シール手段を備える光ディスク成形用金型装置
US5827658A (en) 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US5726022A (en) 1996-11-18 1998-03-10 Lifespan Biosciences, Inc. Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences
CA2272820C (en) 1996-11-20 2012-09-11 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5958738A (en) 1997-03-24 1999-09-28 Roche Diagnostics Corporation Procedure for subtractive hybridization and difference analysis
US6261570B1 (en) 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
GB9716611D0 (en) 1997-08-07 1997-10-08 Cantab Pharmaceuticals Res Ltd Virus preparations and methods
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6197502B1 (en) 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
US7005275B2 (en) * 1998-03-27 2006-02-28 Cytos Biotechnology Ag Inducible alphaviral gene expression system
EP1069908B1 (de) 1998-04-08 2010-02-10 The University of North Carolina at Chapel Hill Krebsimpfstoff enthaltend alphavirusrepliconpartikeln
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
AU767551B2 (en) 1998-06-29 2003-11-13 U.S. Medical Research Institute Of Infectious Diseases Marburg virus vaccines
US6770479B1 (en) 1998-07-10 2004-08-03 The United States Of America As Represented By The Secretary Of The Army Anthrax vaccine
WO2000002523A2 (en) 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Department Of The Army Vaccine against staphylococcus intoxication
CA2336587A1 (en) 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Botulinum neurotoxin vaccine
EP1117430A1 (de) 1998-10-05 2001-07-25 Genzyme Corporation In krebszellen differentiell exprimierte gene zur herstellung von krebsimpfstoffen
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6242259B1 (en) * 1998-12-31 2001-06-05 Chiron Corporation Compositions and methods for packing of alphavirus vectors
US6602705B1 (en) 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
US6329201B1 (en) * 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
AU4366000A (en) 1999-04-14 2000-11-14 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6495743B1 (en) * 1999-06-28 2002-12-17 University Of Hawaii Plant xylanases
ATE412763T1 (de) 1999-08-31 2008-11-15 Univ North Carolina Antikörper-abhängige vergrösserung der alphavirus-infektvität
DK1285080T3 (da) 2000-05-31 2008-12-01 Novartis Vaccines & Diagnostic Fremgangsmåde til oprensning af alphavirusreplikonpartikler
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
AU2001273313A1 (en) 2000-07-07 2002-01-21 Alphavax, Inc. Alphavirus vectors and virosomes with modified hiv genes for use as vaccines
JP3544925B2 (ja) * 2000-07-27 2004-07-21 株式会社東芝 番組予約機能を備えた放送受信システムとその放送受信装置及び番組予約端末
JP3814251B2 (ja) 2000-07-28 2006-08-23 ビステオン グローバル テクノロジーズ インコーポレイテッド 内燃機関の空気取入れ装置
JP2004507249A (ja) * 2000-08-29 2004-03-11 ワイス・ホールディングズ・コーポレイション プラス鎖ｒｎａウイルスレプリコン粒子のパッケージング
WO2002020721A2 (en) 2000-09-07 2002-03-14 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
US6800289B2 (en) * 2000-12-21 2004-10-05 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Strain of the western equine encephalitis virus
WO2002080982A2 (en) 2001-01-12 2002-10-17 Chiron Corporation Nucleic acid mucosal immunization
WO2002099035A2 (en) * 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
ATE437222T1 (de) 2001-09-06 2009-08-15 Alphavax Inc Alphavirus replikon-vektorsysteme
WO2003083065A2 (en) 2002-03-25 2003-10-09 University Of North Carolina At Chapel Hill Improved methods for achieving expression from alphavirus vectors
JP3857195B2 (ja) 2002-07-09 2006-12-13 株式会社東芝 距離継電装置
AU2003295470A1 (en) 2002-11-13 2004-06-03 The United States Of America As Represented By The Secretary Of The Navy Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines
BR122019005271B1 (pt) 2002-12-13 2020-10-13 Alphavax, Inc. método para a preparação de partículas de replicon de alfavírus (arps)
JP4991108B2 (ja) 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
DK1608762T3 (da) 2003-03-20 2014-04-07 Alphavax Inc Forbedrede alphavirusreplikoner og hjælperkonstrukter
EP1651666B1 (de) 2003-07-11 2009-05-27 Alphavax, Inc. Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren

Also Published As

Publication number Publication date
ATE437222T1 (de) 2009-08-15
EP1432791B2 (de) 2013-10-23
ES2330202T3 (es) 2009-12-07
ES2330202T5 (es) 2014-01-20
EP1432791A1 (de) 2004-06-30
US7045335B2 (en) 2006-05-16
CA2460269C (en) 2013-01-15
US20030119182A1 (en) 2003-06-26
CA2460269A1 (en) 2003-03-20
EP1432791B1 (de) 2009-07-22
WO2003023026A1 (en) 2003-03-20
EP1432791A4 (de) 2005-07-27
US20060177819A1 (en) 2006-08-10
US7425337B2 (en) 2008-09-16
JP2005508159A (ja) 2005-03-31
AU2002327614B2 (en) 2007-12-06
JP4790984B2 (ja) 2011-10-12

Similar Documents

Publication Publication Date Title
DE60233061D1 (de) Alphavirus replikon-vektorsysteme
DE122007000070I1 (de) In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
SI1685243T1 (sl) Imortalizirane ptičje celične linije za produkcijo virusov
MX2007007889A (es) Rescate del virus de influenza.
WO2003054197A3 (de) A librairy of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism
EP1394259A3 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
ATE472335T1 (de) Chimere alphavirus-replikon-partikel
DE50214416D1 (de) Vermehrung von viren in zellkultur
WO2003068923A3 (en) Signal for packaging of influenza virus vectors
SG149003A1 (en) Gene expression technique
ATE432285T1 (de) Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
ATE547511T1 (de) Nichttumorbildende mdck-zellinie zur vermehrung von viren
ATE270342T1 (de) Endosomolytisch wirksame partikel
DK1321477T3 (da) Fremgangsmåde til frembringelsen af genetisk modificerede vertebrate precursor-lymfocytter og anvendelse deraf til fremstillingen af heterologe bindende proteiner
WO2003072725A3 (en) Recombinant negative strand virus rna expression systems and vaccines
MX2023014557A (es) Sistemas crispr-transposon para modificacion de adn.
MXPA04003969A (es) Sistema de expresion de acido nucleico regulado.
EA200600693A1 (ru) Пакующие клетки для рекомбинантных аденовирусов
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
IL175558A0 (en) A universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma
DE122011100041I1 (de) In vitro-rekonstitution von segmentierten, negativstrang-rna-viren.
DE60334097D1 (de) Methode zur herstellung von viralen partikeln welche eine veränderte zellbindungsaktivität haben und deren verwendungen
DK1664087T3 (da) Fjernelse af prioner ved anvendelse af metaloxidpartikler
EP1309342A4 (de) Herstellung eines chimeren papillomavirus(22.01.2)
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same

Legal Events

Date Code Title Description
8363 Opposition against the patent